Effects of Triptorelin Versus Placebo on the Symptoms of Endometriosis

Bergqvist A, A Bergqvist, Agneta Bergqvist, T. Bergh, Bergh T, Hogström L, Lars Hogström, L Hogström, S.E. Mattsson, S Mattsson, Mattsson S, F Nordenskjöld, Nordenskjöld F, Fredrik Nordenskjöld, Carsten Rasmussen, Rasmussen C, C Rasmussen
Fertility and sterility · 1998 · vol. 69(4) , pp. 702–708 · doi:10.1016/s0015-0282(98)00019-3 · PMID:9548161 · W2073040347
article OA: closed CC0 ⤵ 75 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated the effects of triptorelin compared to placebo on the symptoms of endometriosis, assessing treatment efficacy and tolerability.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo compare the effect of a GnRH-agonist, triptorelin, versus placebo on the symptoms of endometriosis.DesignA prospective, randomized, double-blind study of 6 months of treatment followed by 12 months of follow-up.SettingDepartments of Obstetrics and Gynecology at two universities and one general hospital.Patient(s)Forty-nine women with symptoms of laparoscopically verified endometriosis.Intervention(s)Triptorelin depot or placebo was given every 4 weeks. Clinical evaluation, including the Duration Intensity Behavior Scale and Visual Analogue Scale for pain, was performed before the injections and up to 12 months after treatment. A control laparoscopy was performed 4-6 weeks after the last injection.Main outcome measure(s)Quantitation of pain.Result(s)Twenty-four patients had active treatment and 25 received placebo. Pain symptoms according to both scales were significantly more reduced after 2 months of triptorelin treatment compared to placebo. The extent of endometriotic lesions was reduced 50% during triptorelin treatment and increased 17% during placebo. The average area of endometriotic lesions was reduced 45% during triptorelin treatment but was unchanged during placebo. Side effects, mainly hot flushes, were experienced by 80% of the actively treated group but also by 33% of patients in the placebo group. Because of recurrent symptoms, only five patients could be observed for 12 months after completion of treatment.Conclusion(s)Triptorelin reduces endometriotic lesions and pain to a significantly higher degree than placebo.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Luteolytic Agents Pain Measurement Pelvic Pain Triptorelin Pamoate Adult Delayed-Action Preparations Double-Blind Method Endometriosis Endometriosis Female Follow-Up Studies Humans Luteolytic Agents Luteolytic Agents Luteolytic Agents Pain Measurement Patient Dropouts Pelvic Pain Pelvic Pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (22)

Cited by (50)

Source provenance

europepmc
last seen: 2026-08-27T06:11:05.884134+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:40.754221+00:00
unpaywall
last seen: 2026-08-27T06:26:25.619941+00:00
License: CC0 · commercial use OK